NCT06394492View on ClinicalTrials.gov

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

SHR-A1921

SHR-A1921 dose 1

DRUG

Doxorubicin

Doxorubicin dose 2

DRUG

Paclitaxel

Paclitaxel dose 3

DRUG

Topotecan

Topotecan dose 4

Trial Locations (2)

100021

RECRUITING

National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY